The investigators undertook a retrospective analysis of patients with advanced urothelial carcinoma who were longitudinally tested for ctDNA (MTM/mL) with a tumor-informed assay while on treatment ...

The firm will study AKY-1189 in Nectin-4-expressing tumors, including urothelial and triple-negative breast cancer.

The FDA has granted clearance to the IND applications for both the therapeutic ( [ 225 Ac]Ac-AKY-1189) and imaging ( [ 64 ...

Strong Growth in U.S. Market with Favorable Reimbursement Policies and Rising Kidney Stone Procedures Fuel National and Global Demand for Flexible and Single-Use Ureteroscopes.Austin, May 29, 2025 ...

Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC). This is ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will ...

Welcome to The Pharma Letter ’s real-time coverage of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

CheckMate 274 is a phase III, randomized, double-blind trial of adjuvant nivolumab versus placebo for muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence after radical resection.

USA-based UroGen Pharma, a biotech developing and commercializing innovative solutions that treat urothelial and specialty ...

The following is a summary of “Impact of concomitant medications on the oncologic efficacy of systemic therapy in patients ...